ARS Pharmaceuticals Inc — Liquidità Trimestrale (NASDAQ:SPRY)

Financials

Totale attivo 351.15 M327.32 M313.47 M372.8 M327.65 M Totale passività 94.36 M98.34 M121.15 M225.15 M213.39 M Patrimonio netto totale 256.8 M228.97 M192.32 M147.66 M114.26 M Totale passività e patrimonio netto 351.15 M327.32 M313.47 M372.8 M327.65 M Debito totale ———97.76 M96.37 M Indebitamento netto ———-190.45 M-148.61 M

Notizie

Health Canada approva lo spray nasale neffy per allergie gravi

Northland avvia la copertura su ARS Pharmaceuticals con rating outperform

William Blair conferma Outperform su ARS Pharma dopo aggiornamento FDA

ARS Pharmaceuticals: Neffy's Slow Launch, No Guidance For 2026 Keep Me On Sidelines (SPRY)

Leerink alza il target su ARS Pharmaceuticals per espansione vendite

Leerink raises ARS Pharmaceuticals stock price target on sales expansion

ARS Pharmaceuticals batte le previsioni del Q4 2025, azioni in rialzo

Earnings call transcript: ARS Pharmaceuticals beats Q4 2025 forecasts, stock rises

ARS Pharmaceuticals, Inc. (SPRY) Q4 2025 Earnings Call Transcript

Gli EPS di ARS Pharmaceuticals hanno battuto le aspettative per 0,01$, il fatturato supera le previsioni

ARS Pharmaceuticals earnings beat by $0.01, revenue topped estimates

ARS Pharmaceuticals, Inc. (SPRY) Reports Q4 Loss, Beats Revenue Estimates